另外，马斯克近日在社交媒体上表示，其脑机接口公司Neuralink将于2026年开始对脑机接口设备进 行"大规模生产"。 | 代码 | 名称 | | 涨幅% ↓ | 总市值 | 年初至今涨幅% | | --- | --- | --- | --- | --- | --- | | 688580 | 伟思医疗 | 1 | 20.01 | 66.75亿 | 44.01 | | 301293 | 三博脑科 | 1 | 20.01 | 175亿 | 44.01 | | 688626 | 翔宇医疗 | 1 | 20.00 | 139亿 | 44.00 | | 300753 | 爰朋医疗 | 1 | 20.00 | 50.37 乙 | 44.00 | | 301330 | 熵基科技 | 1 | 19.99 | 112亿 | 43.99 | | 301363 | 美好医疗 | 1 | 19.99 | 197亿 | 43.99 | | 688273 | 麦澜德 | 1 | 19.99 | 61.22 亿 | 43.98 | | 300430 | 诚益通 | 1 | 18.47 | 74.60亿 | 42.14 | | 30040 ...

Market Overview - The Shanghai Composite Index (沪指) continued to rise, reaching 4057 points, surpassing the previous high from November 14, 2025, and marking the highest level since July 2015 [1] - The index achieved a record of 12 consecutive daily gains, the longest since 1993, with the previous record being 11 consecutive gains [6] Brain-Computer Interface Sector - Companies in the brain-computer interface sector, such as Xiangyu Medical (翔宇医疗) and Aipeng Medical (爱朋医疗), experienced significant stock price increases, with both reaching the daily limit of a 20% rise [1] - Other medical companies like Meihua Medical (美好医疗) and Chuangxin Medical (创新医疗) also saw substantial gains, with increases of approximately 20% and 10% respectively [2] Solid-State Battery Sector - The solid-state battery concept saw a surge in early trading, with companies like Puli Te (普利特) and Jinlongyu (金龙羽) hitting their daily price limits, while others like Aotwei (奥特维) and Daoshi Technology (道氏技术) rose over 10% [2] - Donut Lab, a Finnish electric mobility technology company, announced the launch of the world's first commercially viable solid-state battery at the CES 2026, emphasizing its readiness for production [5] - According to Zhongjin Company, solid-state batteries are expected to achieve technical stabilization and small-scale production by 2027, with commercial production anticipated by 2030, and demand projected to exceed 150 GWh [5] Investment Outlook - Analysts from Dongzheng Futures and Debang Securities suggest that the current market sentiment is positive, with technology stocks expected to remain a key focus in the near term [6] - The market is anticipated to continue its upward trend, supported by the performance of heavyweight sectors such as insurance, which could enhance the sustainability of the rally [6]

本报记者 刘钊 1月6日开盘，A股脑机接口概念板块延续强势，多只个股快速封板。截至记者发稿，其中伟思医疗（688580.SH）、三 博脑科（301293）（301293.SZ)、翔宇医疗（688626.SH）、爱朋医疗（300753）（300753.SZ)、美好医疗（301363） （301363.SZ）等多只个股20cm涨停，麦澜德（688273.SH）、诚益通（300430）（300430.SZ）、熵基科技 （301330）（301330.SZ）、博拓生物（688767.SH）等多只个股涨幅居前。 | 물을 | 代码 | 名称 | | 最新 | 涨幅% ↓ | 涨跌 | 成交量 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 688580 | 伟思医疗 | 1 | 69.70 | 20.01 | 11.62 | 8.70万 | | 2 | 301293 | 三博脑科 | 1 | 84.94 | 20.01 | 14.16 | 2.63万 | | 3 | 688626 | 翔宇医疗 | 1 | 87.12 | 20.00 | 14.52 | ...

1月6日盘中科创板股翔宇医疗涨停，截至09:34，股价报87.12元，成交4.86亿元，换手率3.55%，振幅 6.97%。 融资融券数据显示，该股最新（1月5日）两融余额为2.06亿元，其中，融资余额为2.05亿元，较上一个 交易日增加1088.40万元，增幅为5.60%；融券余额为45.74万元，较上一个交易日增加7.62万元，增幅为 20.00%。近10日两融余额合计增加3433.94万元，增幅为20.05%，其间融资余额增长20.01%，融券余额 增长42.10%。（数据宝） （文章来源：证券时报网） 科创板个股中，截至发稿上涨的有389只，下跌的有198只，涨幅居前的有翔宇医疗、高测股份、伟思医 疗等，分别上涨20.00%、16.73%、16.60%，跌幅居前的有新光光电、兴图新科、源杰科技等，分别下 跌8.91%、5.47%、5.30%。 资金面上，翔宇医疗上一交易日主力资金净流入7339.93万元，近5日净流入1.29亿元。 ...

Core Viewpoint - A-shares have experienced a significant rally, with the Shanghai Composite Index reaching a new high not seen since July 2015, indicating strong market sentiment and potential for continued growth in the technology sector [1][4]. Market Performance - As of the latest data, the Shanghai Composite Index is at 4054.25, up by 30.83 points (+0.77%), while the Shenzhen Component Index and the Sci-Tech Innovation Index also showed positive movements [2]. - The A-share market has achieved a remarkable 12 consecutive days of gains, marking the longest streak since 1993, with previous records being 11 consecutive days in 2006 and 2017-2018 [3]. Sector Highlights - The brain-computer interface sector is witnessing explosive growth, with companies like Xiangyu Medical and Aipeng Medical hitting the 20% daily limit up [2]. - Other notable performers include Meihua Medical, Innovation Medical, and Aerospace Changfeng, all showing significant percentage increases [3]. Future Outlook - Analysts from Dongzheng Futures and Debon Securities suggest that the current market sentiment is optimistic, with expectations for a "slow bull" market trend to continue, particularly in technology stocks [4][5]. - The report indicates that sectors such as commercial aerospace, artificial intelligence, and robotics are expected to remain in focus, alongside cyclical sectors like oil and non-ferrous metals [5]. Hong Kong Market Performance - In the Hong Kong market, tech stocks are also performing well, with JD Health rising over 6% and other companies like XPeng and NetEase seeing gains of over 3% [5][6].

Core Insights - The medical device sector is experiencing a strong upward trend, with the CSI All Index Medical Device Index rising by 1.25% and significant gains in key stocks such as Meihua Medical and Xiangyu Medical [1] - Neuralink, owned by Elon Musk, plans to begin large-scale production of brain-machine interface devices in 2026, aiming for a streamlined and automated surgical process [1] - The brain-machine interface has been included in China's 14th Five-Year Plan, with specific goals for technological breakthroughs by 2027 and industry strength by 2030 [1] Market Performance - The medical device ETF (159883) has seen a 1.16% increase, with net subscriptions exceeding 400 million units [1] - The latest net inflow into the medical device ETF is 274 million yuan [1] Industry Developments - Domestic high-end medical device market share is increasing, with over 70% penetration of domestic DR and ultrasound diagnostic equipment in grassroots medical institutions [2] - The brain-machine interface industry is expected to enter a growth phase, transitioning from research to commercialization, supported by policy and technological advancements [2] - The brain-machine interface market is projected to grow at a CAGR of 17% from 2025 to 2034, reaching an estimated $12.4 billion by 2034 [2] ETF Insights - The medical device ETF (159883) has the highest brain-machine interface content in the market, accounting for over 23% of its holdings, and focuses on innovative domestic companies [3] - The Hong Kong medical ETF (159366) tracks a medical theme index, providing exposure to high-quality assets in the medical device sector, including minimally invasive brain science and robotics [3]

北京商报讯（记者 丁宁）1月6日，延续前一交易日大涨走势，人脑工程板块涨幅明显。 具体来看，三博脑科、美好医疗开盘"20cm"涨停，爱朋医疗、翔宇医疗等高开超10%。 ...

Core Insights - The announcement by Elon Musk regarding Neuralink's mass production of brain-machine interface (BMI) devices has significantly boosted market confidence in the commercialization of this technology, leading to a surge in related A-share stocks on the first trading day of 2026 [2][3][10] Group 1: Market Reaction - On January 5, 2026, domestic BMI concept stocks collectively opened high, with companies like Beikang rising over 29.98% and several others hitting the daily limit of 20% [1] - The market's positive response reflects high expectations for the commercial prospects of brain-machine interfaces following Musk's announcements [2][3] Group 2: Neuralink's Developments - Neuralink has completed seven rounds of financing, raising over $1.3 billion, which is significant compared to the projected $2.9 billion global market size for BMIs in 2025 [3][4] - The company has achieved several milestones, including FDA approval for human clinical trials and the first human implantation of a BMI, marking its leadership in the field [3][4] Group 3: Clinical Advancements in China - 2025 was termed the "Year of Chinese Brain-Machine Interfaces," with numerous clinical breakthroughs in restoring motor and speech abilities for high-level paraplegics, visual reconstruction, and treatment of mental disorders [7][8][10] - Key clinical trials have been conducted by various institutions, demonstrating significant advancements in BMI technology and its applications [9] Group 4: Regulatory and Market Developments - The introduction of policies such as the inclusion of BMIs in medical insurance and the establishment of regulatory frameworks for BMI medical devices indicate a move towards commercialization [10] - In 2025, the Chinese BMI sector saw 24 financing rounds, a 30% increase year-on-year, signaling growing investor interest and confidence in the market [10] Group 5: Competitive Landscape - Despite the surge in stock prices, there are currently no pure-play BMI companies listed in China, with many firms still in the process of developing their products and seeking IPO opportunities [11][12] - Companies like Qiangnao Technology and Bori Kang are actively pursuing IPOs, indicating a competitive race to become the first publicly listed BMI company in China [12][13] Group 6: Future Outlook - The industry is expected to enter a commercialization phase in 2026, with a competitive landscape emerging as various companies aim to establish themselves in the market [14]

Core Viewpoint - The A-share market started 2026 on a positive note, with all three major indices rising, indicating a shift from valuation recovery in 2025 to profit-driven growth in 2026 [1][5]. Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to 4023.42 points, the Shenzhen Component Index increased by 2.24% to 13828.63 points, and the ChiNext Index saw a rise of nearly 2.9% to 3294.55 points [5]. - The total trading volume reached 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [5]. Sector Highlights - Key sectors showing strong performance included brain-computer interfaces, insurance, and storage devices, with significant gains in AI applications and emerging industries [2][6]. - The brain-computer interface sector experienced a surge, with related stocks hitting the daily limit, driven by news from overseas about Neuralink's plans for large-scale production [7][9]. Investment Outlook - Analysts predict that the 2026 technology bull market is likely to continue, with a focus on sectors such as technology growth, advanced manufacturing, and cyclical consumption [2][12]. - Investment strategies for 2026 include a balanced approach of high-quality stocks and high-potential sectors, emphasizing technology companies with strong fundamentals and emerging industries [13]. Structural Opportunities - The pharmaceutical sector is expected to see structural opportunities driven by innovation, international expansion, and policy reforms, with a focus on innovative drugs and AI integration in healthcare [14].

真没想到，脑机接口概念股又爆了！ 今年第一个交易日，脑机接口板块再次爆发，板块内51家成分股中有29家涨停，涨幅超过10%达到了惊人的40家。 1月5日，河南上市公司翔宇医疗（证券代码：688626.SH）收获今年首个20CM涨停，报收于72.6元/股，创下四年半来的新高。事实上，在经历近4个月的 回调后，自去年12月12日以来，翔宇医疗已经重拾涨势，15个交易日累计涨幅达到53%。 在此期间，公司获得接连不断的机构调研，12月22日—29日，公司陆续发布2则公告，近10天时间里接待了71家机构。 股价15天涨了53% 自去年以来，翔宇医疗的股价表现可谓抢眼。截至今年1月5日，翔宇医疗股价已经累计上涨了149.06%。 1月5日，翔宇医疗时隔半年再次收获"20CM"涨停，股价创下四年半来的新高。 翔宇医疗于2021年3月31日登陆A股上市，上市初始出现一波大涨，在当年6月28日盘中创出120.13元的历史最高点。 回顾翔宇医疗上市以来的走势可以看到，他们在2021年6月下旬创出120.13元历史最高点，之后就开始走出了长达3年的下跌行情，一直到2024年9月，翔 宇医疗整体趋势就是震荡走低，但是中间波动还是比 ...